Detecting P. falciparum and P. vivax

This paper reviews the sensitivity and specificity of RDTs for detecting P. falciparum and P. vivax in two different settings ¿ at health centres and in a household survey. The study includes a large number of patients (2,394 participants) and provides useful additional information about the performance of these RDTs.

Woyessa A, Deressa W, Ali A, Lindtjørn B. Evaluation of CareStartTM malaria Pf/Pv combo test for Plasmodium falciparum and Plasmodium vivax malaria diagnosis in Butajira area, south-central Ethiopia. Malaria Journal 2013, 12:218 doi:10.1186/1475-2875-12-218

Abstact:

Malaria is a major public health problem in Ethiopia. Plasmodium falciparum and Plasmodium vivax co-exist and malaria rapid diagnostic test (RDTs) is vital in rendering parasite-confirmed treatment especially in areas where microscopy is not available. CareStartTM Malaria Pf/Pv combo test was evaluated compared to microscopy in Butajira area, south-central Ethiopia. This RDT detects histidine-rich protein-2 (HRP2) found in P. falciparum, and Plasmodium enzyme lactate dehydrogenase (pLDH) for diagnosis of P. vivax 2008-2010. The standard for the reporting of diagnostic accuracy studies was complied. Among 2,394 participants enrolled, 10.9% (n=87) were Plasmodium infected (household survey) and 24.5% (n=392) using microscopy. In the household surveys, the highest positivity was caused by P. vivax (83.9%, n=73), P. falciparum (15.0%, n=13), and the rest due to mixed infections of both (1.1%, n=1). In health facility, P. vivax caused 78.6% (n=308), P. falciparum caused 20.4% (n=80), and the rest caused by mixed infections 1.0% (n=4). RDT missed 9.1% (n=8) in household and 4.3% (n=17) in health facility-based surveys among Plasmodium positive confirmed by microscopy while 3.3% (n=24) in household and 17.2% (n=208) in health facility-based surveys were detected false positive. RDT showed agreement with microscopy in detecting 79 positives in household surveys (n=796) and 375 positives in health centre survey (n=1,598).RDT performance varied in both survey settings, lowest PPV (64.3%) for Plasmodium and P. falciparum (77.2%) in health centres; and Plasmodium (76.7%) and P. falciparum (87.5%) in household surveys. NPV was low in P. vivax in health centres (77.2%) and household (87.5%) surveys. Seasonally varying RDT precision of as low as 14.3% PPV (Dec. 2009), and 38.5% NPV (Nov. 2008) in health centre surveys; and 40-63.6% PPV was observed in household surveys. But the influence of age and parasite density on RDT performance was not ascertained. Establishing quality control of malaria RDT in the health system in areas with low endemic and P. falciparum and P. vivax co-exist is recommendable. CareStartTM RDT might be employed for epidemiological studies that require interpreting the results cautiously. Future RDT field evaluation against microscopy should be PCR corrected.

Malaria Research at Haukeland University Hospital

The National Centre for Tropical Infectious Diseases at the Department of Medicine at the Haukeland University Hospital in Bergen (Norway) represents one of the main centres for treating patients with tropical diseases in Norway. They work in close collaboration with the University of Bergen.

During the last years they have published the following articles on malaria:

Haanshuus CG, Mohn SC, Mørch K, Langeland N, Blomberg B, Hanevik K. A novel, single-amplification PCR targeting mitochondrial genome highly sensitive and specific in diagnosing malaria among returned travellers in Bergen, Norway . Malaria Journal 2013, 12:26 (22 January 2013)

Mørch K, Myrvang B. Treatment of malaria in Norway. Tidsskr Nor Laegeforen 2012 Mar;132(6):664-7. PMID: 22456148

Calleri G, Behrens RH, Schmid ML, Gobbi F, Grobusch MP, Castelli F, Gascon J, Bisoffi Z, Jelinek T, Caramello P. Malaria chemoprophylaxis recommendations for immigrants to Europe, visiting relatives and friends-a Delphi method study. Malar J 2011;10():137. Epub 2011 mai 20. PMID: 21599909

Zoller T, Junghanss T, Kapaun A, Gjorup I, Richter J, Hugo-Persson M, Mørch K, Foroutan B, Suttorp N, Yürek S, Flick H. Intravenous artesunate for severe malaria in travelers, Europe. Emerg Infect Dis 2011 May;17(5):771-7. PMID: 21529383

Mørch K, Strand Ø, Dunlo OO, Berg A, Langeland N, Leiva RAM, Longva JÅ, Sjursen H, Skrede S, Sundal J, Jensenius M. Severe malaria and artesunate treatment, Norway. Emerging Infectious Diseases 2008 Nov;11(14):1816-1818 2.

Berg A, Patel S, Langeland N, Blomberg B. Falciparum malaria and HIV-1 in hospitalized adults in Maputo, Mozambique: does HIV-infection obscure the malaria diagnosis?  Malar J. 2008 Dec 15;7(1):252.

Morch K, Feruglio SL, Ormaasen V, Bruun JN. [Severe falciparum malaria treated with exchange transfusion] Tidsskr Nor Laegeforen. 2002 Apr 20;122(10):999-1001

Strand EA, Strand OA, Hellum KB, Smith-Erichsen N, Myrvang B.  [A young, stuporous and afebrile man with icterus and nosebleed]. Tidsskr Nor Laegeforen. 2002 Feb 28;122(6):619-23. 

Update on MalTrials project

In January 2013 we finalised all agreements regarding the Norwegian Research Council grant regarding the MalTrials project: Combining indoor residual spraying and long-lasting insecticidal nets for preventing malaria: Cluster randomised trial in Ethiopia.

This note presents an update on the progress of the planned work:

  • Ethical clearance: We have applied for ethical permission to start the project, and we hope to get these permissions in July.
  • Once we get permission from Ethiopian authorities, we plan to start some pilot studies on:
    • Map the areas, and identify potential hot spots for malaria transmission
    • Select three kebeles (about 30 Gares, villages). We shall measure the incidence; find out the variation in incidence between the villages. This will enable us to calculate the correct sample size for our trial.
    • Start some entomological studies.
  • We have recruited three PhD students:
    • Taye Gari (epidemiology)
    • Alemayehu Desalegn (Health economics)
    • Oljira Kenea (Entomology)
  • We plan to start the main malaria trial in early 2014.